Enhancing immune responses to tumor-associated antigens

Cancer Biology and Therapy

Volumn 8, Issue 15, 2009, Pages

  Higgins, Jack P ^a   Bernstein, Michael B ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Costimulation; Immunotherapy; Tumor associated antigen; Vaccine

Indexed keywords

ANTINEOPLASTIC AGENT; B7 ANTIGEN; CANCER VACCINE; CYTOKINE; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; TOLL LIKE RECEPTOR; TUMOR ANTIGEN;

CLINICAL TRIAL; DRUG POTENTIATION; ELECTROCOAGULATION; FEMALE; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; MALE; METHODOLOGY; MULTIMODALITY CANCER THERAPY; NEOPLASM; REVIEW; T LYMPHOCYTE SUBPOPULATION; TUMOR ESCAPE;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ANTIGENS, CD80; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYTOKINES; ELECTROCOAGULATION; FEMALE; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; MALE; NEOPLASMS; SELF TOLERANCE; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTORS; TUMOR ESCAPE;

EID: 85046914987     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.8.15.9133     Document Type: Review

References (138)

1. Wiemann B, Starnes CO. Coley's toxins, tumor necrosis factor and cancer research: a historical perspective. Pharmacol Ther 1994; 64:529-564 (Pubitemid 24381235)
2. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, et al. The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 1992; 52:6380-6384
3. De Plaen E, Lurquin C, Van Pel A, Mariame B, Szikora JP, Wolfel T, et al. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum-antigen P91A and identification of the tum-mutation. Proc Natl Acad Sci USA 1988; 85:2274-2278
4. Mandelboim O, Berke G, Fridkin M, Feldman M, Eisenstein M, Eisenbach L. CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature 1994; 369:67-71. (Pubitemid 24144356)
5. Sahin U, Tureci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995; 92:11810-11813 (Pubitemid 26014201)
6. Viatte S, Alves PM, Romero P. Reverse immunology approach for the identification of CD8 T-cell-defined antigens: advantages and hurdles. Immunol Cell Biol 2006; 84:318-330
7. Terabe M, Berzofsky JA. The role of NKT cells in tumor immunity. Adv Cancer Res 2008; 101:277-348.
8. Hofmeister V, Schrama D, Becker JC. Anti-cancer therapies targeting the tumor stroma. Cancer Immunol Immunother 2008; 57:1-17. (Pubitemid 350043655)
9. + T lymphocytes) in the control of human tumors. Cancer Immunol Immunother 2009; 58:801-808
10. Fournier P, Schirrmacher V. Randomized clinical studies of anti-tumor vaccination: state of the art in 2008. Expert Rev Vaccines 2009; 8:51-66.
11. Li G, Ali SA, McArdle SE, Mian S, Ahmad M, Miles A, et al. Immunity to tumour antigens. Curr Pharm Des 2005; 11:3501-3509
12. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol 2009; 27:83-117.
13. Lans TE, Grunhagen DJ, de Wilt JH, van Geel AN, Eggermont AM. Isolated limb perfusions with tumor necrosis factor and melphalan for locally recurrent soft tissue sarcoma in previously irradiated limbs. Ann Surg Oncol 2005; 12:406-411
14. Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289-296 (Pubitemid 34032623)
15. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-2116
16. Fagerberg J. Granulocyte-macrophage colony-stimulating factor as an adjuvant in tumor immunotherapy. Med Oncol 1996; 13:155-160 (Pubitemid 27207219)
17. Allison AC. The mode of action of immunological adjuvants. Dev Biol Stand 1998; 92:3-11.
18. Coronel A, Boyer A, Franssen JD, Romet-Lemonne JL, Fridman WH, Teillaud JL. Cytokine production and T-cell activation by macrophage-dendritic cells generated for therapeutic use. Br J Haematol 2001; 114:671-680 (Pubitemid 32953650)
19. Harzstark AL, Small EJ. Sipuleucel-T for the treatment of prostate cancer. Drugs Today (Barc) 2008; 44:271-278
20. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006; 24:3089-3094
21. Herper M. Data Shows Provenge Extends Cancer Survival. Available from: http://www.forbes.com/2009/04/28/dendreon-provenge-cancer-business-healthcare- dendreon.html.
22. Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy. Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00065442.
23. Bendandi M, Gocke CD, Kobrin CB, Benko FA, Sternas LA, Pennington R, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med 1999; 5:1171-1177 (Pubitemid 29474422)
24. Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma (BiovaxID). Available from: http://www.clinicaltrials.gov/ ct2/results?term=NCT00091676+.
25. Ullenhag GJ, Frodin JE, Jeddi-Tehrani M, Strigard K, Eriksson E, Samanci A, et al. Durable carcinoembryonic antigen (CEA)-specific humoral and cellular immune responses in colorectal carcinoma patients vaccinated with recombinant CEA and granulocyte/macrophage colony-stimulating factor. Clin Cancer Res 2004; 10:3273-3281 (Pubitemid 38685431)
26. Ward JE, McNeel DG. GVAX: an allogeneic, whole-cell, GM-CSF-secreting cellular immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther 2007; 7:1893-1902 (Pubitemid 350247490)
27. Higano CS, Corman JM, Smith DC, Centeno AS, Steidle CP, Gittleman M, et al. Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer 2008; 113:975-984
28. Docetaxel in Combination With GVAX® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients. Available from: http://www. clinicaltrials.gov/ct2/results?term=NCT00133224+.
29. GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer. Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00089856.
30. Parmiani G, Castelli C, Pilla L, Santinami M, Colombo MP, Rivoltini L. Opposite immune functions of GM-CSF administered as vaccine adjuvant in cancer patients. Ann Oncol 2007; 18:226-232 (Pubitemid 46323086)
31. + T-regulatory cells. J Immunother 2006; 29:313-319
32. Daud AI, DeConti RC, Andrews S, Urbas P, Riker AI, Sondak VK, et al. Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma. J Clin Oncol 2008; 26:5896-5903
33. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69:4010-4017
34. Davis ID, Brady B, Kefford RF, Millward M, Cebon J, Skrumsager BK, et al. Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial. Clin Cancer Res 2009; 15:2123-2129
35. Fyfe G, Fisher RI, Rosenberg SA, Sznol M, Parkinson DR, Louie AC. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995; 13:688-696
36. Letourneau S, Krieg C, Pantaleo G, Boyman O. IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets. J Allergy Clin Immunol 2009; 123:758-762
37. Dudek AZ, Mescher MF, Okazaki I, Math VT, Luo X, Curtsinger JM, et al. Autologous large multivalent immunogen vaccine in patients with metastatic melanoma and renal cell carcinoma. Am J Clin Oncol 2008; 31:173-181
38. Elias EG, Zapas JL, McCarron EC, Beam SL, Hasskamp JH, Culpepper WJ. Sequential administration of GM-CSF (Sargramostim) and IL-2 +/- autologous vaccine as adjuvant therapy in cutaneous melanoma: an interim report of a phase II clinical trial. Cancer Biother Radiopharm 2008; 23:285-291
39. Sosman JA, Carrillo C, Urba WJ, Flaherty L, Atkins MB, Clark JI, et al. Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol 2008; 26:2292-2298
40. Acres B, Bonnefoy JY. Clinical development of MVA-based therapeutic cancer vaccines. Expert Rev Vaccines 2008; 7:889-893
41. Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B, et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs 2008; Epub ahead of print.
42. Tran KQ, Zhou J, Durflinger KH, Langhan MM, Shelton TE, Wunderlich JR, et al. Minimally cultured tumor-infiltrating lymphocytes display optimal characteristics for adoptive cell therapy. J Immunother 2008; 31:742-751
43. Ward RC, Kaufman HL. Targeting costimulatory pathways for tumor immunotherapy. Int Rev Immunol 2007; 26:161-196
44. Dols A, Smith JW, 2nd, Meijer SL, Fox BA, Hu HM, Walker E, et al. Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther 2003; 14:1117-1123
45. Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, et al. Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res 2008; 14:4843-4849
46. Kaufman HL, Deraffele G, Mitcham J, Moroziewicz D, Cohen SM, Hurst-Wicker KS, et al. Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 2005; 115:1903-1912 (Pubitemid 40979730)
47. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006; 12:1260-1269 (Pubitemid 43342517)
48. Arlen PM, Skarupa L, Pazdur M, Seetharam M, Tsang KY, Grosenbach DW, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urol 2007; 178:1515-1520 (Pubitemid 47368382)
49. Hodge JW, Chakraborty M, Kudo-Saito C, Garnett CT, Schlom J. Multiple costimulatory modalities enhance CTL avidity. J Immunol 2005; 174:5994-6004. (Pubitemid 40663786)
50. Gulley JL, Arlen PM, Tsang KY, Yokokawa J, Palena C, Poole DJ, et al. Pilot study of vaccination with recombinant CEA-MUC-1-TRICOM poxviral-based vaccines in patients with metastatic carcinoma. Clin Cancer Res 2008; 14:3060-3069
51. Weber J. Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 2009; 58:823-830
52. Weber JS, O'Day S, Urba W, Powderly J, Nichol G, Yellin M, et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008; 26:5950-5956
53. Fong L, Kwek SS, O'Brien S, Kavanagh B, McNeel DG, Weinberg V, et al. Potentiating endogenous antitumor immunity to prostate cancer through combination immunotherapy with CTLA4 blockade and GM-CSF. Cancer Res 2009; 69:609-615
54. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003; 100:8372-8377 (Pubitemid 36842552)
55. Tong AW, Stone MJ. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther 2003; 10:1-13. (Pubitemid 36222071)
56. Eliopoulos AG, Davies C, Knox PG, Gallagher NJ, Afford SC, Adams DH, et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol Cell Biol 2000; 20:5503-5515 (Pubitemid 30482887)
57. Vonderheide RH, Flaherty KT, Khalil M, Stumacher MS, Bajor DL, Hutnick NA, et al. Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol 2007; 25:876-883
58. Medzhitov R, Janeway C Jr. Innate immunity. N Engl J Med 2000; 343:338-344
59. Meyer T, Stockfleth E. Clinical investigations of Toll-like receptor agonists. Expert Opin Investig Drugs 2008; 17:1051-1065
60. Vidal D. Topical imiquimod: mechanism of action and clinical applications. Mini Rev Med Chem 2006; 6:499-503.
61. + T-cell lymphoma responsive to topical imiquimod (Aldara). Br J Dermatol 2004; 150:1198-1201
62. Schon MP, Schon M. The small-molecule immune response modifier imiquimod - its mode of action and clinical use in the treatment of skin cancer. Expert Opin Ther Targets 2006; 10:69-76. (Pubitemid 43263267)
63. Stary G, Bangert C, Tauber M, Strohal R, Kopp T, Stingl G. Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells. J Exp Med 2007; 204:1441-1451 (Pubitemid 46919881)
64. Guiducci C, Coffman RL, Barrat FJ. Signalling pathways leading to IFNalpha production in human plasmacytoid dendritic cell and the possible use of agonists or antagonists of TLR7 and TLR9 in clinical indications. J Intern Med 2009; 265:43-57.
65. Shackleton M, Davis ID, Hopkins W, Jackson H, Dimopoulos N, Tai T, et al. The impact of imiquimod, a Toll-like receptor-7 ligand (TLR7L), on the immunogenicity of melanoma peptide vaccination with adjuvant Flt3 ligand. Cancer Immun 2004; 4:9. (Pubitemid 39363886)
66. Adams S, O'Neill DW, Nonaka D, Hardin E, Chiriboga L, Siu K, et al. Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant. J Immunol 2008; 181:776-784
67. + hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009; 69:917-927
68. Jurk M, Vollmer J. Therapeutic applications of synthetic CpG oligodeoxynucleotides as TLR9 agonists for immune modulation. BioDrugs 2007; 21:387-401. (Pubitemid 350145447)
69. Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, et al. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3979-3986
70. Coley Pharma announces Pfizer's discontinuation of clinical trials for PF-3512676. Available from: http://www.reuters.com/article/inPlayBriefing/ idUSIN-20070620135825COLY20070620.
71. GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer. Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00480025.
72. Vansteenkiste J, Zielinski M, Linder A, Dahabre J, Esteban E, Malinowski W, et al. Final results of a multi-center, double-blind, randomized, placebo-controlled phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2007; 25:7554.
73. Vansteenkiste J, Zielinski M, Dahabre J, Linder A, Lehmann F, Gruselle O, et al. Association of gene expression signature and clinical efficacy of MAGE-A3 antigen-specific cancer immunotherapeutic (ASCI) as adjuvant therapy in resected stage IB/II non-small cell lung cancer (NSCLC). J Clin Oncol 2008; 26:7501.
74. Kanodia S, Kast WM. Peptide-based vaccines for cancer: realizing their potential. Expert Rev Vaccines 2008; 7:1533-1545
75. Valmori D, Souleimanian NE, Tosello V, Bhardwaj N, Adams S, O'Neill D, et al. Vaccination with NY-ESO-1 protein and CpG in montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc Natl Acad Sci USA 2007; 104:8947-8952 (Pubitemid 47175417)
76. + T cells in melanoma patients. J Immunother 2008; 31:781-791
77. Ribi E, Cantrell JL, Takayama K, Qureshi N, Peterson J, Ribi HO. Lipid A and immunotherapy. Rev Infect Dis 1984; 6:567-572
78. Baldridge JR, McGowan P, Evans JT, Cluff C, Mossman S, Johnson D, et al. Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents. Expert Opin Biol Ther 2004; 4:1129-1138 (Pubitemid 38937554)
79. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol 2005; 23:6674-6681 (Pubitemid 46190262)
80. Cancer Vaccine Study for Unresectable Stage III Non-Small Cell Lung Cancer. Available from: http://www.clinicaltrials.gov/ct2/results?term= NCT00409188.
81. Baxevanis CN, Perez SA, Papamichail M. Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy. Cancer Immunol Immunother 2009; 58:317-324
82. Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003; 170:4905-4913 (Pubitemid 36554719)
83. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003; 63:4490-4496
84. Tanaka F, Yamaguchi H, Ohta M, Mashino K, Sonoda H, Sadanaga N, et al. Intratumoral injection of dendritic cells after treatment of anticancer drugs induces tumor-specific antitumor effect in vivo. Int J Cancer 2002; 101:265-269 (Pubitemid 34970895)
85. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-1701 (Pubitemid 41815875)
86. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004; 173:7125-7130 (Pubitemid 39628146)
87. Muranski P, Boni A, Wrzesinski C, Citrin DE, Rosenberg SA, Childs R, et al. Increased intensity lymphodepletion and adoptive immunotherapy - how far can we go? Nat Clin Pract Oncol 2006; 3:668-681
88. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006; 12:878-887 (Pubitemid 43259871)
89. Hodge JW, Guha C, Neefjes J, Gulley JL. Synergizing radiation therapy and immunotherapy for curing incurable cancers. Opportunities and challenges. Oncology (Williston Park) 2008; 22:1064-1070
90. Demaria S, Formenti SC. Sensors of ionizing radiation effects on the immunological microenvironment of cancer. Int J Radiat Biol 2007; 83:819-825 (Pubitemid 350219096)
91. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61. (Pubitemid 46067386)
92. Reits EA, Hodge JW, Herberts CA, Groothuis TA, Chakraborty M, Wansley EK, et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006; 203:1259-1271 (Pubitemid 43736595)
93. Garnett CT, Palena C, Chakraborty M, Tsang KY, Schlom J, Hodge JW. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res 2004; 64:7985-7994 (Pubitemid 39446933)
94. Demaria S, Santori FR, Ng B, Liebes L, Formenti SC, Vukmanovic S. Select forms of tumor cell apoptosis induce dendritic cell maturation. J Leukoc Biol 2005; 77:361-368 (Pubitemid 40289566)
95. Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res 2005; 11:3353-3362 (Pubitemid 40627887)
96. Chi KH, Liu SJ, Li CP, Kuo HP, Wang YS, Chao Y, et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. J Immunother 2005; 28:129-135 (Pubitemid 40328199)
97. Liu LX, Zhang WH, Jiang HC. Current treatment for liver metastases from colorectal cancer. World J Gastroenterol 2003; 9:193-200. (Pubitemid 36215787)
98. Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res 2006; 66:1139-1146 (Pubitemid 43165983)
99. Zerbini A, Pilli M, Fagnoni F, Pelosi G, Pizzi MG, Schivazappa S, et al. Increased immunostimulatory activity conferred to antigen-presenting cells by exposure to antigen extract from hepatocellular carcinoma after radiofrequency thermal ablation. J Immunother 2008; 31:271-282
100. Fietta AM, Morosini M, Passadore I, Cascina A, Draghi P, Dore R, et al. Systemic inflammatory response and downmodulation of peripheral CD25(+)Foxp3(+) T-regulatory cells in patients undergoing radiofrequency thermal ablation for lung cancer. Hum Immunol 2009; Epub ahead of print.
101. Fagnoni FF, Zerbini A, Pelosi G, Missale G. Combination of radiofrequency ablation and immunotherapy. Front Biosci 2008; 13:369-381
102. Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology 2009; 58:1-11.
103. Alblin RJ, Soanes WA, Gonder MJ. Prospects for cryo-immunotherapy in cases of metastasizing carcinoma of the prostate. Cryobiology 1971; 8:271-279
104. Ablin RJ, Guinan PD, Bruns GR, Sheik HI, Sadoughi N, Bush IM. Evaluation of cellular immunologic responsiveness in the clinical management of patients with prostatic cancer II. Effect of oestrogen, cryosurgery and transurethral resection on thymic-dependent lymphocytic blastogenesis. Urol Int 1976; 31:383-400.
105. Ablin RJ, Bruns GR, Guinan PD, Sadoughi N, Sheik HA, Bush IM. Alterations in host responsiveness in patients with prostatic cancer following cryosurgery or transurethral resection. Am Surg 1977; 43:144-150
106. Weyer U, Petersen I, Ehrke C, Carstensen A, Nussgen A, Russ C, et al. Immunomodulation by cryosurgery in malignant melanoma. Onkologie 1989; 12:291-296
107. Osada S, Imai H, Tomita H, Tokuyama Y, Okumura N, Matsuhashi N, et al. Serum cytokine levels in response to hepatic cryoablation. J Surg Oncol 2007; 95:491-498 (Pubitemid 46709393)
108. Si T, Guo Z, Hao X. Immunologic response to primary cryoablation of high-risk prostate cancer. Cryobiology 2008; 57:66-71.
109. Zhang HG, Mehta K, Cohen P, Guha C. Hyperthermia on immune regulation: a temperature's story. Cancer Lett 2008; 271:191-204.
110. Kennedy JE. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer 2005; 5:321-327 (Pubitemid 40488637)
111. Wu F. Extracorporeal high intensity focused ultrasound in the treatment of patients with solid malignancy. Minim Invasive Ther Allied Technol 2006; 15:26-35. (Pubitemid 43203356)
112. Wu F, Wang ZB, Cao YD, Zhou Q, Zhang Y, Xu ZL, et al. Expression of tumor antigens and heat-shock protein 70 in breast cancer cells after high-intensity focused ultrasound ablation. Ann Surg Oncol 2007; 14:1237-1242
113. Lu P, Zhu XQ, Xu ZL, Zhou Q, Zhang J, Wu F. Increased infiltration of activated tumor-infiltrating lymphocytes after high intensity focused ultrasound ablation of human breast cancer. Surgery 2009; 145:286-293
114. Wang D, Dubois RN. Prostaglandins and cancer. Gut 2006; 55:115-122
115. Trifan OC, Hla T. Cyclooxygenase-2 modulates cellular growth and promotes tumorigenesis. J Cell Mol Med 2003; 7:207-222 (Pubitemid 37372041)
116. Soslow RA, Dannenberg AJ, Rush D, Woerner BM, Khan KN, Masferrer J, et al. COX-2 is expressed in human pulmonary, colonic and mammary tumors. Cancer 2000; 89:2637-2645 (Pubitemid 32011609)
117. Lonnroth C, Andersson M, Arvidsson A, Nordgren S, Brevinge H, Lagerstedt K, et al. Preoperative treatment with a non-steroidal anti-inflammatory drug (NSAID) increases tumor tissue infiltration of seemingly activated immune cells in colorectal cancer. Cancer Immun 2008; 8:5.
118. Soo RA, Wu J, Aggarwal A, Tao Q, Hsieh W, Putti T, et al. Celecoxib reduces microvessel density in patients treated with nasopharyngeal carcinoma and induces changes in gene expression. Ann Oncol 2006; 17:1625-1630 (Pubitemid 44680881)
119. Ruter J, Barnett BG, Kryczek I, Brumlik MJ, Daniel BJ, Coukos G, et al. Altering regulatory T cell function in cancer immunotherapy: a novel means to boost the efficacy of cancer vaccines. Front Biosci 2009; 14:1761-1770
120. + regulatory cells augments the generation of specific immune T cells in tumor-draining lymph nodes. J Immunother 2002; 25:207-217
121. Steitz J, Bruck J, Lenz J, Knop J, Tuting T. Depletion of CD25(+) CD4(+) T cells and treatment with tyrosinase-related protein 2-transduced dendritic cells enhance the interferon alpha-induced, CD8(+) T-cell-dependent immune defense of B16 melanoma. Cancer Res 2001; 61:8643-8646
122. Sutmuller RP, van Duivenvoorde LM, van Elsas A, Schumacher TN, Wildenberg ME, Allison JP, et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J Exp Med 2001; 194:823-832
123. + T cells in advanced stages of primary cutaneous T-cell lymphoma. J Invest Dermatol 2006; 126:2217-2223
124. Foss FM. DAB(389) (ONTAK): a novel fusion toxin therapy for lymphoma. Clin Lymphoma 2000; 1:110-116
125. Barnett B, Kryczek I, Cheng P, Zou W, Curiel TJ. Regulatory T cells in ovarian cancer: biology and therapeutic potential. Am J Reprod Immunol 2005; 54:369-377 (Pubitemid 41748714)
126. Rasku MA, Clem AL, Telang S, Taft B, Gettings K, Gragg H, et al. Transient T cell depletion causes regression of melanoma metastases. J Transl Med 2008; 6:12. (Pubitemid 351597459)
127. Dannull J, Su Z, Rizzieri D, Yang BK, Coleman D, Yancey D, et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J Clin Invest 2005; 115:3623-3633 (Pubitemid 43121851)
128. Denileukin Diftitox in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment. Available from: http://www. clinicaltrials.gov/ct2/results?term=NCT00425672.
129. A Pilot Study Evaluating the Efficacy of Regulatory T-Cell Suppression by Ontak in Metastatic Pancreatic Cancer. Available from: http://www. clinicaltrials.gov/ct2/results?term=NCT00726037.
130. Ovarian Dendritic Cell Vaccine Trial. Available from: http://www.clinicaltrials.gov/ct2/results?term=NCT00703105.
131. Tsurushita N, Hinton PR, Kumar S. Design of humanized antibodies: from anti-Tac to Zenapax. Methods 2005; 36:69-83. (Pubitemid 40558817)
132. Waldmann TA. Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey. J Clin Immunol 2007; 27:1-18.
133. Chen J, Zhang M, Ju W, Waldmann TA. Effective treatment of a murine model of adult T-cell leukemia using depsipeptide and its combination with unmodified daclizumab directed toward CD25. Blood 2009; 113:1287-1293
134. Brode S, Cooke A. Immune-potentiating effects of the chemotherapeutic drug cyclophosphamide. Crit Rev Immunol 2008; 28:109-126
135. + regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother 2007; 56:641-648
136. + T lymphocytes. Clin Exp Immunol 2007; 150:523-530
137. Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 2009; 8:40-52.
138. Skak K, Kragh M, Hausman D, Smyth MJ, Sivakumar PV. Interleukin 21: combination strategies for cancer therapy. Nat Rev Drug Discov 2008; 7:231-240